• Mabwell won China NMPA clearance to start clinical trials of its 9MW5211 injection for vitiligo.
• The antibody candidate already has NMPA trial approvals for inflammatory bowel disease, multiple sclerosis, Type 1 diabetes.
• Mabwell also secured US FDA clearance for an inflammatory bowel disease trial application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabwell (Shanghai) Bioscience Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260715-12245555), on July 15, 2026, and is solely responsible for the information contained therein.